Valuation: VolitionRx Limited

Market Cap 6.66M 5.79M 5.41M 4.96M 9.36M 635M 9.52M 63.75M 24.97M 317M 25.03M 24.47M 1.04B P/E 2026 *
-0.36x
P/E 2027 * -0.58x
Enterprise Value 6.66M 5.79M 5.41M 4.96M 9.36M 635M 9.52M 63.75M 24.97M 317M 25.03M 24.47M 1.04B EV / Sales 2026 *
2.69x
EV / Sales 2027 * 1.16x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week-5.44%
Current month+12.10%
1 month-40.37%
3 months-66.32%
6 months-84.51%
Current year-84.25%
1 week 0.69
Extreme 0.6901
0.88
1 month 0.69
Extreme 0.6901
1.53
Current year 0.69
Extreme 0.6901
7.73
1 year 0.69
Extreme 0.6901
15.1
3 years 0.69
Extreme 0.6901
27.6
5 years 0.69
Extreme 0.6901
82.8
10 years 0.69
Extreme 0.6901
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/03/26 Tax

Chief Technology Officer

5,310 0.0039%
17/03/26 Tax

Company Secretary

3,948 0.0029%
01/03/26
Concord International, Inc.
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%-5.44%-93.54%-96.90% 6.66M
+2.61%-18.30%+86.94%+77.95% 3.61B
+1.80%+3.69%+114.02%+241.87% 3.68B
-1.47%+31.29%+272.50%+322.84% 2.48B
+2.61%+3.59%-25.76%-35.18% 2.16B
+1.62%-6.49%+55.30%-39.30% 1.93B
-0.55%-6.92%+181.28%-44.48% 947M
+4.68%-0.89%-3.79%+10.91% 850M
-0.46%+4.93%-38.26%-11.69% 519M
+8.68%+5.01%+11.42% - 464M
Average +1.91%+2.89%+56.01%+47.34% 1.66B
Weighted average by Cap. +1.68%+1.23%+96.91%+110.00%

Financials

2026 *2027 *
Net sales 2.48M 2.15M 2.01M 1.85M 3.48M 236M 3.54M 23.7M 9.28M 118M 9.31M 9.1M 388M 5.73M 4.98M 4.65M 4.27M 8.05M 546M 8.19M 54.85M 21.48M 273M 21.54M 21.06M 899M
Net income -22.2M -19.3M -18.02M -16.54M -31.18M -2.12B -31.73M -212M -83.2M -1.06B -83.4M -81.55M -3.48B -19.62M -17.05M -15.92M -14.61M -27.56M -1.87B -28.04M -188M -73.51M -933M -73.69M -72.06M -3.08B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
-
Date Price Change Volume
04/08/26 US$0.8050 +0.64% 97,994
03/08/26 US$0.7999 +11.39% 203,212
31/07/26 US$0.7181 -10.20% 252,637
30/07/26 US$0.7997 +3.51% 1,006,754
29/07/26 US$0.7726 -9.24% 249,672
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.7999USD
Average target price
16.97USD
Spread / Average Target
+2,021.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock